statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Why Cassava Sciences Stock Is Skyrocketing Today

Why Cassava Sciences Stock Is Skyrocketing Today...

Cassava Sciences Chairman Shares Insights in Open Letter

Cassava Sciences (SAVA) has provided an announcement. Rick Barry, the Executive Chairman of Cassava Sciences, Inc., has penned an Open Letter to th...

Cassava Sciences Faces Leadership Shake-Up, Prioritizes Transparency And Scientific Rigor In Alzheimer's Trials

Cassava Sciences Faces Leadership Shake-Up, Prioritizes Transparency And Scientific Rigor In Alzheimer's Trials...

Shares of Texas-based pharmaceuticals firm Cassava Sciences fell over 29% on Wednesday after its CEO and Chairman Remi Barbier resigned. Retail sentiment on Stocktwits remained in bullish territory (59/100) after briefly dipping into the neutral zone, supported by high message volumes on Wednesday.<figure class="image"><img style="aspect-ratio:781/217;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_07_17_at_11_19_51_AM_dbdf10deb8.png" alt="Retail sentiment remains in bullish territory" width="781" height="217"><figcaption>Retail sentiment on Cassava Sciences remains in bullish territory</figcaption></figure>Meanwhile, Lindsay Burns, SVP of Neuroscience at Cassava, is also leaving the company. With immediate effect, the board of directors has appointed Richard Barry as Executive Chairman and the company’s principal executive officer. Meanwhile, the firm is searching for a new permanent CEO. Cassava Sciences pointed out that the board plans to separate the Chairman and CEO roles by identifying a new CEO.The departure of the key executive comes at a time when the firm has been in the news due to a federal probe. In June, a federal grand jury returned an indictment, charging the firm’s former scientific advisor Hoau-Yan Wang for allegedly defrauding the US National Institutes of Health (NIH). Hoau-Yan Wang was a tenured medical professor at a public university’s medical school as well as a former paid science advisor to Cassava Sciences, it said.Cassava Sciences had pointed out, citing court documents, that Wang engaged in illegal behavior to defraud the government through grant applications made to the NIH, resulting in the award of approximately $16 million in grants from 2017 to 2021 on behalf of himself and the company.Still, the firm has said its primary goal right now is to determine whether Simufilam is an effective, revolutionary treatment for Alzheimer’s disease. However, the distractions and uncertainty have caused the stock to have a tough year so far, losing nearly 60% YTD.The CEO's departure hasn’t gone down well with retail investors, and Stocktwits users are expressing concerns about it. One user named ‘Skies88’ believes the stock could see more downside in the coming months.<figure class="image"><a href="https://stocktwits.com/Skies88/message/579782866"><img style="aspect-ratio:775/140;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_07_17_at_11_21_19_AM_a6e36c83e5.png" alt="Stocktwits user Skies88's post on Cassava Sciences" width="775" height="140"></a><figcaption>Stocktwits user Skies88 expresses bearishness on Cassava Sciences stock</figcaption></figure>&nbsp;

Retail Continues To Remain Bullish On Cassava Sciences Despite Stock Plunging 29% Over CEO Departure 

Cassava Sciences said it is searching for a new CEO and intends to separate this role from the Chairman’s position going forward. Although the stock fell 29% following the news, retail sentiment trended in the bullish territory.

Cassava Sciences fell over 29% on Wednesday

Equity

Cassava Sciences Announces Executive Leadership Reshuffle

Cassava Sciences (SAVA) just unveiled an update. Remi Barbier, President and CEO of Cassava Sciences, resigned effective September 13, 2024, and wi...

Why Cassava Sciences Stock Is Sinking Today

Why Cassava Sciences Stock Is Sinking Today...

Cassava Sciences Cooperates With DOJ, SEC On Controversial Alzheimer's Drug Investigation

Cassava Sciences is cooperating with DOJ and SEC investigations involving its Alzheimer's drug simufilam. An internal committee is examining new SEC information, while the company advances its Phase...

Cassava Shares Are Down Over 30%: Here's Why

Cassava Sciences, Inc. (NASDAQ: SAVA) shares are trading significantly lower on Friday following the indictment of Hoau-Yan Wang, a tenured medical professor and advisor to the company, by a federal...

Cramer's Lightning Round: Cassava Sciences is 'speculative'

"Mad Money" host Jim Cramer rings the lightning round bell, which means he's giving his answers to callers' stock questions at rapid speed...

Peering Into Cassava Sciences's Recent Short Interest

Cassava Sciences, Inc. engages in the development of novel drugs and diagnostics. It focuses on developing product candidates intended for the treatment of Alzheimer’s disease, including PTI-125 and PTI-125Dx. The company was founded by Remi Barbier in May 1998 and is headquartered in Austin, TX.

Volume	3.66M
52-Wk High	$32.10
52-Wk Low	$8.79

SAVA Cassava Sciences Inc

About

Feed

News

Sentiment

Earnings

Fundamentals